References
- Steele JP, Klabatsa A, Fennell DA et al. Prognostic factors in mesothelioma. Lung Cancer49(Suppl. 1), S49–S52 (2005).
- Boutin C, Schlesser M, Frenay C, Astoul P.Malignant pleural mesothelioma. Eur. Respir. J.12(4), 972–981 (1998).
- Hegmans JP, Veltman JD, Lambers ME et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am. J. Respir. Crit. Care Med. DOI: 10.1164/rccm.200909-1465OC (2010) (Epub ahead of print).
- Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol.21(14), 2636–2644 (2003).
- Gregoire M. What’s the place of immunotherapy in malignant mesothelioma treatments? Cell. Adh. Migr.4(1), 153–161 (2010).
- Gregoire M, Ligeza-Poisson C, Juge-Morineau N, Spisek R. Anti-cancer therapy using dendritic cells and apoptotic tumour cells: pre-clinical data in human mesothelioma and acute myeloid leukaemia. Vaccine21(7–8), 791–794 (2003).
- Hegmans JP, Hemmes A, Aerts JG, Hoogsteden HC, Lambrecht BN. Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells. Am. J. Respir. Crit. Care Med.171(10), 1168–1177 (2005).
- Vulink A, Radford KJ, Melief C, Hart DN. Dendritic cells in cancer immunotherapy. Adv. Cancer Res.99, 363–407 (2008).
- Powell A, Creaney J, Broomfield S, Van Bruggen I, Robinson B. Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma. Lung Cancer52(2), 189–197 (2006).
- Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol.5(4), 296–306 (2005).
- Simon T, Fonteneau J-F, Grégoire M. Dendritic cell preparation for immunotherapeutic interventions. Immunotherapy1(2), 289–302 (2009).
- Hegmans JP, Hemmes A, Hammad H, Boon L, Hoogsteden HC, Lambrecht BN. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur. Respir. J.27(6), 1086–1095 (2006).
- Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol.21(2), 233–240 (2009).
- Scherpereel A, Astoul P, Baas P et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur. Respir. J.35(3), 479–495 (2010).
- Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol.8(1), 59–73 (2008).
- McCoy MJ, Nowak AK, Lake RA. Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma. Tissue Antigens74(1), 1–10 (2009).
- Vandermeers F, Hubert P, Delvenne P et al. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin. Cancer Res.15(8), 2818–2828 (2009).
- Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur. J. Cancer44(1), 46–53 (2008).
- Gauvrit A, Brandler S, Sapede-Peroz C, Boisgerault N, Tangy F, Gregoire M. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Cancer Res.68(12), 4882–4892 (2008).
Website
- Clinicaltrials.gov: search using keywords mesothelioma and dendritic www.clinicaltrials.gov/ct2/results?term=mesothelioma+and+dendritic